CR845: New Drug In Development Treats Pain, Inflammation Without Side Effects Or Addiction
Cara Therapeutics is a biotechnology firm that is developing a new painkilling, anti-inflammatory drug, also known as CR845, that could rival oxycodone in the medical marketplace. If eventually approved by the Food and Drug Administration (FDA) it would be used to treat conditions such as hip and knee pain.
The CEO of Cara, Derek Chalmers, says that CR845 is set to offer a more potent treatment for both acute and chronic pain than over-the-counter pain relievers, yet would curtail addiction as it does not penetrate the blood-brain barrier or act on the body’s central nervous system.
Chalmers, as reported by the Stamford Advocate:
“By shutting down the nerve activity at the site of injury, it can produce … anti-inflammatory activity in the absence of a central nervous system brain effect…”
“The drug is entirely non-addicting.”
The drug also works to mitigate pruritus (itching.) In clinical trials, CR845 has shown significant reductions in “itch intensity” and efficacy in patients with moderate to severe pain without invoking unwanted side effects often associated with opioid therapy.
Per the Cara Therapeutics website, CR845, the drug induces little or no side effects typically seen with prescription opioids, such as nausea, vomiting, sedation, respiratory depression, or euphoria, and has no real potential for abuse or addiction.
According to the MMJ Reporter, Chalmers says that the company has begun trials for oral CR845 for the treatment of itching in persons with kidney disease, and another study has commenced that is testing the use of CR845 intravenously to target acute post-op pain in patients undergoing abdominal surgery.
Cara is planning to file its first new drug application with the Food and Drug Administration within the next two years.
~ G. Nathalee Serrels, M.A., Psychology